Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells

BACKGROUND: Pancreatic cancer (PC) is the fourth most common cause of cancer death. Combination therapies with classical chemotherapeutic agents improved treatment of advanced PC at the cost of a relevant toxicity, but the 5-year survival rate remains below 5%. Consequently, new therapeutic options...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Exp Clin Cancer Res
Autors principals: Veschi, Serena, De Lellis, Laura, Florio, Rosalba, Lanuti, Paola, Massucci, Alberto, Tinari, Nicola, De Tursi, Michele, di Sebastiano, Pierluigi, Marchisio, Marco, Natoli, Clara, Cama, Alessandro
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6151049/
https://ncbi.nlm.nih.gov/pubmed/30241558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-018-0904-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars